BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29761078)

  • 1. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
    Hu B; Oki Y
    Front Oncol; 2018; 8():139. PubMed ID: 29761078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of new immunotherapy targets for NK/T cell lymphoma.
    Lv K; Li X; Yu H; Chen X; Zhang M; Wu X
    Am J Transl Res; 2020; 12(11):7034-7047. PubMed ID: 33312349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updating targets for natural killer/T-cell lymphoma immunotherapy.
    Xue W; Zhang M
    Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of new drugs in extranodal NK/T-cell lymphoma.
    Wang L; Li LR; Zhang L; Wang JW
    Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.
    Cho SG; Kim N; Sohn HJ; Lee SK; Oh ST; Lee HJ; Cho HI; Yim HW; Jung SE; Park G; Oh JH; Choi BO; Kim SW; Kim SW; Chung NG; Lee JW; Hong YS; Kim TG
    Mol Ther; 2015 Aug; 23(8):1401-1409. PubMed ID: 26017177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
    Costa RO; Pereira J; Lage LAPC; Baiocchi OCG
    Front Oncol; 2023; 13():1175545. PubMed ID: 37529691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
    Tse E; Au-Yeung R; Kwong YL
    Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
    Tse E; Kwong YL
    Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in immunotherapy of extranodal NK/T cell lymphoma].
    Hao DQ; Li LQ; Li MC; Gong LL
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Dec; 54(12):949-953. PubMed ID: 31887826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of extranodal NK/T-cell lymphoma: From past to future.
    Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
    Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBV and the Pathogenesis of NK/T Cell Lymphoma.
    Montes-Mojarro IA; Fend F; Quintanilla-Martinez L
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy of Programmed Cell Death Ligand 1 Antibody in Treatment of Extranodal Natural Killer/T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis.
    Yang CL; Chen X; Zhou HJ; Wu WC; Zou LQ
    J Hematol; 2024 Apr; 13(1-2):46-51. PubMed ID: 38644986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances and challenges of immunotherapies in NK/T cell lymphomas.
    He L; Chen N; Dai L; Peng X
    iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK/T-cell lymphomas.
    Tse E; Kwong YL
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):253-261. PubMed ID: 31585625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare case of low-grade extranodal NK/T-cell lymphoma, nasal type, arising in the setting of chronic rhinosinusitis and harboring a novel N-terminal KIT mutation.
    Devins K; Schuster SJ; Caponetti GC; Bogusz AM
    Diagn Pathol; 2018 Nov; 13(1):92. PubMed ID: 30470245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances of treatment for extranodal NK/T-cell lymphoma --- review].
    Zhang SS; Wei M; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1075-8. PubMed ID: 21867647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience.
    Ávila Milord AA; Aguilar Hernández MM; Demichelis Gómez R; Agreda Vásquez GP
    Blood Res; 2018 Sep; 53(3):210-217. PubMed ID: 30310787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.